Arcturus Therapeutics (ARCT) Tops Q2 EPS by 38c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.64), $0.38 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $49.86 million versus the consensus estimate of $32.26 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
• Gyre Therapeutics (GYRE) files for 30.22M share offering by selling stockholders